| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent N Mottet, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 243-262, 2021 | 2008 | 2021 |
| EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer P Cornford, RCN van den Bergh, E Briers, T Van den Broeck, ... European urology 79 (2), 263-282, 2021 | 786 | 2021 |
| Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review T Van den Broeck, RC Van Den Bergh, N Arfi, T Gross, L Moris, E Briers, ... European urology 75 (6), 967-987, 2019 | 397 | 2019 |
| EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international … TBL Lam, S MacLennan, PPM Willemse, MD Mason, K Plass, R Shepherd, ... European urology 76 (6), 790-813, 2019 | 212 | 2019 |
| Biochemical recurrence in prostate cancer: the European Association of Urology prostate cancer guidelines panel recommendations T Van den Broeck, RCN van den Bergh, E Briers, P Cornford, ... European urology focus 6 (2), 231-234, 2020 | 167 | 2020 |
| Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review L Moris, MG Cumberbatch, T Van den Broeck, G Gandaglia, N Fossati, ... European urology 77 (5), 614-627, 2020 | 142 | 2020 |
| Novel insights into the management of oligometastatic prostate cancer: a comprehensive review A Battaglia, G De Meerleer, L Tosco, L Moris, T Van den Broeck, G Devos, ... European urology oncology 2 (2), 174-188, 2019 | 68 | 2019 |
| Drivers of AR indifferent anti-androgen resistance in prostate cancer cells F Handle, S Prekovic, C Helsen, T Van den Broeck, E Smeets, L Moris, ... Scientific reports 9 (1), 13786, 2019 | 55 | 2019 |
| Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy … PPM Willemse, NF Davis, N Grivas, F Zattoni, M Lardas, E Briers, ... European Urology 81 (4), 337-346, 2022 | 48 | 2022 |
| Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer G Devos, W Devlies, G De Meerleer, M Baldewijns, T Gevaert, L Moris, ... Nature Reviews Urology 18 (12), 739-762, 2021 | 48 | 2021 |
| Advances in stem cell research for the treatment of male sexual dysfunctions MA Soebadi, L Moris, F Castiglione, E Weyne, M Albersen Current Opinion in Urology 26 (2), 129-139, 2016 | 40 | 2016 |
| The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer L Tosco, A Laenen, A Briganti, P Gontero, RJ Karnes, M Albersen, ... Prostate cancer and prostatic diseases 20 (4), 407-412, 2017 | 35 | 2017 |
| A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: limitations of the available evidence and … AS Bates, J Ayers, N Kostakopoulos, T Lumsden, IG Schoots, ... European Urology Oncology 4 (3), 405-423, 2021 | 33 | 2021 |
| Patient-and tumour-related prognostic factors for urinary incontinence after radical prostatectomy for nonmetastatic prostate cancer: a systematic review and meta-analysis M Lardas, N Grivas, TPA Debray, F Zattoni, C Berridge, M Cumberbatch, ... European urology focus 8 (3), 674-689, 2022 | 32 | 2022 |
| Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy U Milenkovic, M Akand, L Moris, L Demaegd, T Muilwijk, Y Bekhuis, ... World Journal of Urology 37, 1857-1866, 2019 | 30 | 2019 |
| Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery T Van den Broeck, L Moris, T Gevaert, L Tosco, E Smeets, N Fishbane, ... European urology oncology 2 (5), 589-596, 2019 | 29 | 2019 |
| A systematic review of the impact of surgeon and hospital caseload volume on oncological and nononcological outcomes after radical prostatectomy for nonmetastatic prostate cancer T Van den Broeck, D Oprea-Lager, L Moris, M Kailavasan, E Briers, ... European Urology 80 (5), 531-545, 2021 | 26 | 2021 |
| Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection L Moris, T Van den Broeck, L Tosco, A Van Baelen, P Gontero, RJ Karnes, ... Frontiers in surgery 3, 65, 2016 | 25 | 2016 |
| Metastasectomy for visceral and skeletal oligorecurrent prostate cancer A Battaglia, G Devos, K Decaestecker, M Witters, L Moris, ... World Journal of Urology 37, 1543-1549, 2019 | 23 | 2019 |
| The androgen receptor depends on ligand‐binding domain dimerization for transcriptional activation S El Kharraz, V Dubois, ME van Royen, AB Houtsmuller, E Pavlova, ... EMBO reports 22 (12), e52764, 2021 | 21 | 2021 |
Thomas Van den BroeckGZA Hospitals Antwerp
Thomas Van den BroeckGZA Hospitals Antwerp